Articles Archives - Page 279 of 714

TuesdayMar 29, 2022 9:15 am

American Cannabis Partners Strong Contender as Opportunities to Market Products Increase

“Between government regulations and rigid policies from Big Tech, marketing cannabis will keep you on your toes,” HID article observes Article forecasts more brands will move to platforms that have cannabis-friendly community guidelines ACP positioning itself in four sectors of cannabis space: real estate, cultivation, medical research and nonprofit groups As the cannabis landscape continues to shift, with growing numbers of states allowing some form of the substance and federal legislation examining changes in legal status, cannabis companies such as American Cannabis Partners (“ACP”) will see increasing opportunities to market their products. “Between government regulations and rigid policies from Big…

TuesdayMar 29, 2022 9:15 am

Sneak Peek at NobleCon18’s Current Lineup of Keynotes & Moderators

Designed to merge ideas with investment, NobleCon18 (the first full in-person NobleCon since February 2020) will feature 100+ carefully selected emerging growth public companies. With total attendance limited to 1,000, this ideal-sized event will provide investors with more direct access to executive teams over the course of the two-day conference. Taking place at The Guitar Hotel near Miami on April 20 and 21, the conference agenda will feature multiple presentation tracks, hundreds of scheduled meetings and breakouts, engaging panel discussions offering varied insights on a range of relevant topics, and unlimited opportunities for networking. Here is the latest list of…

TuesdayMar 29, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Texas-based CNS Pharmaceuticals is a novel brain cancer drug developer that is building a series of global clinical trials for its lead drug candidate, Berubicin CNS began dosing patients in a global trial last September to evaluate Berubicin in treating glioblastoma multiforme (“GBM”), currently an incurable brain cancer CNS received FDA Fast Track designation for Berubicin in June 2021 and FDA Orphan Drug designation for Berubicin in June 2020 Berubicin is a novel anthracycline capable of crossing the blood-brain barrier The company received approval from Switzerland’s swissethics organization for Berubicin trials there, boosting CNS’s efforts at a global response to…

TuesdayMar 29, 2022 9:00 am

Correlate Infrastructure Partners Inc. (CIPI) Is ‘One to Watch’

CIPI closed on acquisitions of subsidiaries Correlate and Solar Site Design on December 28, 2021 The company has filed with the SEC to change its name to Correlate Infrastructure Partners Inc. CIPI subsidiaries have a project pipeline of over $100 million, with more than $20 million in awarded backlog The company’s total addressable market is more than 5.9 million commercial buildings in U.S., representing a market value of $290 billion in 2022 Correlate Infrastructure Partners (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment…

TuesdayMar 29, 2022 9:00 am

Hero Technologies Inc. (HENC) CEO Talks ‘Foot in the Door’ Acquisitions in Recent Bell2Bell Podcast

HENC is focusing on expansion of current operations, future growth in industry Company aims to be a low-cost, nationally and internationally branded company, become true multistate operator (“MSO”) Recent podcast provides overview of company’s strategic plans, important milestones Key acquisitions and investments have played an essential role in Hero Technologies’ (OTC: HENC) strategic business plan and operations. As a featured guest during a recent episode of the Bell2Bell Podcast (https://ibn.fm/J3DGC), company CEO Gina Serkasevich discussed HENC’s careful expansion moves. In 2020, “both Highly Relaxing and the assets of V Brokers, under Veteran Hemp Co., were acquired,” said Serkasevich as she discussed…

MondayMar 28, 2022 9:15 am

Kronos Advanced Technologies Inc. (OTC: KNOS) Air Purifier Features Most Effective Technology Available

Air purifiers can improve indoor air quality, help soothe allergy and asthma symptoms, and rid air of toxins. Kronos’s proprietary, medical-grade technology has been tested as the most effective clean-air solution on the market. An air purifier “may be the household investment to make this year” (“USA Today”) The global pandemic has drawn attention to the fact that airborne particles can be dangerous, even life threatening. Kronos Advanced Technologies (OTC: KNOS) has developed one of the most effective air purifiers available today. One study attributed over two million deaths annually to indoor air pollution (https://ibn.fm/pwSst). Air purifiers are part of…

MondayMar 28, 2022 9:15 am

DGE’s 2nd Real World Evidence and Market Access Symposium to Access High Quality Data to Meet the Patient Needs

Life science executives are invited to attend the 2nd Real World Evidence and Market Access Symposium being held as a virtual event on April 11-12, 2022. The event is hosted by DGE, a leading global event management company that caters to the dynamic informational and networking needs of the pharmaceutical, biotechnology, health care, medical devices, and allied industries. The event centers around discussions, keynotes and sessions about the latest advances and best practices for harnessing real-world data insights that are productive for patients, payers and providers. Organizations can strengthen their business and reimbursement strategies by identifying and accessing the correct…

MondayMar 28, 2022 9:00 am

Delic Holdings Corp’s (CSE: DELC) (OTCQB: DELCF) Co-Founder and CEO Offers a Glimpse into the Company’s History and Future on The Jesse Tee Show

While appearing on The Jesse Tee Show, the company’s co-founder and CEO, Matt Stang, shared his professional background, Delic’s history, its growth, and its plans going forward Mr. Stang attributes its success to understanding where opportunities and people connect, how to make things win-win for all people, and giving customers value Founded in 2016, Delic Holdings Corp now has a market cap of $4.32 million as of March 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF) has been at the forefront of reframing the psychedelic conversation. It has also remained committed to bringing science-backed benefits of psychedelics to the health industry,…

MondayMar 28, 2022 9:00 am

Autonomous Security Robot Developer Knightscope Inc. (NASDAQ: KSCP) Explains IP Advantage as Nasdaq Listing Gains Attention

Artificial intelligence-enhanced security devices and big data collection are gaining popularity as means for strengthening companies’ footprints, particularly in response to criminal activity that can otherwise weaken operations Knightscope is a Silicon Valley-based company developing Autonomous Security Robots (“ASRs”) in response to America’s security needs, delivering a variety of models that observe and report on activity at client properties using powerful technological services Knightscope completed public listing on the Nasdaq Exchange in January 2022, enhancing awareness of its products and generating new inquiries about the nature of its services The company has taken note of its successes with its clients,…

MondayMar 28, 2022 9:00 am

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Novel drug development company Mydecine Innovations Group is focusing on a medicinal pipeline for psychedelic drug candidates that have established some efficacy in treating mental illnesses — specifically addiction Mydecine is progressing in its clinical trial evaluation of its lead candidate, MYCO-001, and is finalizing an IND application with the FDA to begin patient dosing for its planned Phase 2 trials The company is targeting nicotine addiction in tobacco smokers Mydecine is also advancing its evaluation of other drug candidates with pending patents to enhance its existing products Medical-use psychedelic drug product developer Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF)…

Site Search

Company Search

Category: Articles

American Cannabis Partners Strong Contender as Opportunities to Market Products Increase

Sneak Peek at NobleCon18’s Current Lineup of Keynotes & Moderators

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Provides Update on Advances in Brain Cancer Drugs and Operational Financials

Correlate Infrastructure Partners Inc. (CIPI) Is ‘One to Watch’

Hero Technologies Inc. (HENC) CEO Talks ‘Foot in the Door’ Acquisitions in Recent Bell2Bell Podcast

Kronos Advanced Technologies Inc. (OTC: KNOS) Air Purifier Features Most Effective Technology Available

DGE’s 2nd Real World Evidence and Market Access Symposium to Access High Quality Data to Meet the Patient Needs

Delic Holdings Corp’s (CSE: DELC) (OTCQB: DELCF) Co-Founder and CEO Offers a Glimpse into the Company’s History and Future on The Jesse Tee Show

Autonomous Security Robot Developer Knightscope Inc. (NASDAQ: KSCP) Explains IP Advantage as Nasdaq Listing Gains Attention

Psychedelic Medicine Researcher Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Readies IND Application to Advance Drug Trials

Market Basics

Newsletter Publishers

Public Companies